Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) has reported E.P.S. of $-1.37 for its fourth fiscal quarter (ending September 30) versus $-1.02 for the same period a year ago — an increase of 34%. E.P.S. were $-5.00 for the latest four quarters through September 30 versus $-1.92 for the same period a year ago — an increase of 160%.
Recent Price Action
On 11/26/24, Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) stock enjoyed a major increase of 12.0%, closing at $21.05. Moreover, this advance was accompanied by exceptionally high trading volume at 672% of normal. Relative to the market the stock has been weak over the last nine months but has risen 10.7% during the last week.
Current PriceTarget Research Rating
Arrowhead Pharmaceuticals has a current Value Trend Rating of F (Lowest Rating). The Value Trend Rating reflects highly consistent signals from PTR’s two proprietary measures of a stock’s attractiveness. Arrowhead Pharmaceuticals has a very low Appreciation Score of 7 and a very low Power Rating of 5, resulting in the Lowest Value Trend Rating.
Rating Review
In light of this new information and very positive price change we are reviewing our current Overall Rating of F. This review will be completed in the next several days.
Be the first to comment